Global Ulcerative Colitis Market Size, Share & Industry Trends Analysis Report By Molecule Type (Small Molecules and Biologics), By Disease Type, By Route of Administration, By Regional Outlook and Forecast, 2022 - 2028

The Global Ulcerative Colitis Market size is expected to reach $9 billion by 2028, rising at a market growth of 5.7% CAGR during the forecast period.

The global ulcerative colitis market is primarily driven by an increase in the incidence of inflammatory gastrointestinal illnesses, an increase in ulcerative colitis cases, and the development of ulcerative colitis-specific medications by a large number of important companies. As per the survey conducted by Marc D Basson on Ulcerative Colitis in 2019, ulcerative colitis affects one million persons in the United States. The high prevalence of ulcerative colitis is the driving force behind the development of ulcerative colitis medications. As the prevalence of inflammatory bowel illness rises, demand for ulcerative colitis rises, which is expected to fuel the growth of the ulcerative colitis market.

The most common kind of inflammatory bowel illness, ulcerative colitis (UC), affects a large number of people. It is widespread in most of Europe and North America, but rare in most developing Asian countries. Males are more likely to develop UC, which has a north-to-south variance. One possible cause is disparities in ultraviolet light exposure, which results in relative vitamin D insufficiency in countries near the Arctic. People who reside in lower latitudes are more prone than those who live in higher latitudes to develop UC. According to a study published in the National Center for Biotechnology Information (NCBI) in June 2020, the global incidence of ulcerative colitis is 9 to 20 cases per 100,000 people per year. The annual prevalence ranges from 156 to 291 cases per 100,000 people. Adults are more likely to develop ulcerative colitis. Nonsmokers and individuals who have just quit smoking are more likely to develop ulcerative colitis.

If ulcerative colitis is left untreated for more than 8 years, it can progress to colon cancer. Over-the-counter medications like Imodium treatment can help those with moderate symptoms of this condition. Transcription drugs such as steroid pharmaceuticals and aminosalicylates, on the other hand, are commonly used to treat the illness. In extreme situations, surgery to remove the colon may be required, which also helps to prevent colon cancer. Ulcerative colitis is also treated with several genetically modified medicines. These medications are composed of living organisms that assist to reduce inflammation by targeting inflammatory proteins like cytokines. Adalimumab (Humira), Golimumab (Simponi), Infliximab (Remicade), and Vedolizumab are among the genetically modified medications authorized by the US FDA for treating the illness (Entyvio).

COVID-19 Impact Analysis

COVID-19 has acted as a threat multiplier in all areas of life. The medical and psychosocial effects of the COVID-19 pandemic and pre-existing medical conditions like acute severe ulcerative colitis are multidirectional and include the effects of COVID-19 and acute severe ulcerative colitis on each other, as well as their effects on patients, their families, the healthcare system, and health-care providers. According to a study published in the Gastroenterology and Hepatology Journal in February 2021, the risk of COVID-19-related side events is greater in patients with ulcerative colitis. It remains a hazard to people with acute severe ulcerative colitis, posing an ever-increasing threat to the worldwide healthcare system. According to a paper published in June 2020 in the Inflammatory Intestinal Diseases Journal, managing inflammatory bowel disease (IBD) patients (Ulcerative Colitis and Crohn's disease) during the COVID-19 pandemic has been difficult.

Market Growth Factors:

Rising incidences of Ulcerative proctitis

Ulcerative proctitis is one of the kinds of ulcerative colitis that is becoming more common. Fine ulcerations in the inner linings of the large intestine mucosa are visible, and it is thought to be the first sign of ulcerative colitis. According to a study published in the United European Gastroenterology Journal in March 2021, the COVID-19 incidence rate per 1,000 patients with inflammatory bowel disease (ulcerative colitis) and the general population was 4.02 and 6.59, respectively. Hospitalization and intensive care unit care were required by 27.29 percent and 5.33 percent of COVID-19-positive inflammatory bowel disease patients, respectively.

The rise in ulcerative colitis patients and commercialization and an infusion of healthcare capital

The availability of sophisticated ulcerative colitis medications as a result of technological breakthroughs, as well as the growing patient pool in need of treatment, are two main catalytic drivers for the market. In addition, increased demand for symptomatic treatments, the influx of enhancing medications into the market, and increased acceptance of steroids and biologics to treat ulcerative colitis are the major trends in the Ulcerative Colitis Market. Due to increased demand for ulcerative colitis, a shortage of medication, tailored therapy, and curative therapy for ulcerative colitis, the ulcerative colitis industry is likely to offer attractive market prospects.

Marketing Restraining Factor:

Concerns about patent expiry and concerns about negative side effects

The expiration of drug patents is posing a constant threat to the industry players and their revenue. There are few trustworthy medications on the market for ulcerative colitis. Failures, on the other hand, occur when patents are not renewed. The pharmaceutical industry generates the most income of any industry. UC medicines have a high level of investment and production. Patent expiration, on the other hand, can have an impact on all of these processes; capital waste is a big factor that can affect revenue rates. The ulcerative colitis market has had a lot of patent failures in recent years. It is resulting in catastrophic losses.

Molecule Type

Based on Molecule Type, the market is segmented into Small Molecules and Biologics. In 2021, the Small Molecules segment obtained the maximum revenue share of the Ulcerative Colitis Market. This is due to the large number of important players offering medications for ulcerative colitis treatment and advancement in R&D operations. Moreover, many players are putting heavy investments in creating effective medications, thereby boosting the growth of the segment.

Disease Type

Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. The Moderate UC segment held a significant revenue share of the Ulcerative Colitis Market in 2021. Urgent bowel motions, frequent bowel movements, abdominal pain, and cramps are just a few of the painful and sometimes debilitating symptoms of moderate ulcerative colitis. Managing the symptoms with medication and effective home remedies can enhance the quality of life and help a person avoid flare-ups in the future.

Route of Administration

Based on Route of Administration, the market is segmented into Oral and Injectables. In 2021, the Oral segment garnered the biggest revenue share of the Ulcerative Colitis Market. This is due to increased R&D activities in the pharmaceutical & medical device industry, growing demand for drugs required for treatment, and a surge in adoption of various types of ulcerative colitis drugs. Moreover, many people prefer to take medications through oral mode rather than injections, hence boosting the growth of the segment during the forecasting period.

Ulcerative Colitis Market Report Coverage

Report Attribute	Details
Market size value in 2021	USD 6.2 Billion
Market size forecast in 2028	USD 9 Billion
Base Year	2021
Historical Period	2018 to 2020
Forecast Period	2022 to 2028
Revenue Growth Rate	CAGR of 5.7% from 2022 to 2028
Number of Pages	188
Number of Tables	330
Report coverage	Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling
Segments covered	Molecule Type, Disease Type, Route of Administration, Region
Country scope	US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers	Rising incidences of Ulcerative proctitis The rise in ulcerative colitis patients and commercialization and an infusion of healthcare capital
Restraints	Concerns about patent expiry and concerns about negative side effects

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, North America emerged as the leading region in the overall Ulcerative Colitis Market by collecting the maximum revenue share. The high growth of the segment is because of the rise in the number of ulcerative colitis patients, the presence of important companies, the expansion of the healthcare sector, and the presence of new medications in the region. Because of the presence of important companies and the rising prevalence of Ulcerative Colitis in the region, as well as continued financing for the development of new therapies for the treatment of the ailment, North America is likely to lead the ulcerative colitis market.

Free Valuable Insights: Global Ulcerative Colitis Market size to reach USD 9 Billion by 2028

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.

Strategies deployed in Ulcerative Colitis Market

• Mar-2022: Pfizer completed the acquisition of Arena Pharmaceuticals, an American biopharmaceutical company. Through this acquisition, the company aimed to adjoin the amazing pipeline and experience of Arena Pharmaceuticals to Pfizer’s Immunology and swelling healing area, assisting further motive of advancement boost to change the lives of patients with the immuno-inflammatory illness.
• Mar-2021: InDex Pharmaceuticals signed an agreement with Parexel Biotech, a trusted global clinical research organization. Through this agreement, the companies would assess the effectiveness and security of the drug consumer cobitolimod for the therapy of average to critical left-sided ulcerative colitis.
• Feb-2021: Merck signed an agreement to acquire Pandion, a clinical-stage biotechnology enterprise designing novel therapeutics. Through this acquisition, Merck, via a subsidiary, would commence a tender provide to acquire all remaining shares of Pandion. Additionally, this acquisition aimed to definite conditions, such as the tender shares representing at least a greatest number of Pandion’s shares of completely-diluted common stock, the termination of the waiting period under the Hart-Scott-Rodino Antitrust enhancement Act, and other conventional situations.
• Mar-2018: Pfizer received a Food and Drug Administration approval for XELJANZ, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients in the U.S with average to serious active ulcerative colitis. Through this approval, XELJANZ would offer adults living with average to serious active ulcerative colitis now have an oral choice that assists accomplish and preserve steroid-free remission.

Scope of the Study

Market Segments Covered in the Report:

ByMolecule Type

• Small Molecules
• Biologics

By Disease Type

• Mild
• Moderate
• Severe

By Route of Administration

• Oral
• Injectables

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• Abbott Laboratories
• Ajinomoto Co., Inc.
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Pfizer, Inc.
• Sanofi S.A.
• InDex Pharmaceuticals Holding AB
• Eli Lilly And Company

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Ulcerative Colitis Market, by Molecule Type
1.4.2 Global Ulcerative Colitis Market, by Disease Type
1.4.3 Global Ulcerative Colitis Market, by Route of Administration
1.4.4 Global Ulcerative Colitis Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Strategies deployed in Ulcerative Colitis Market

Chapter 4. Global Ulcerative Colitis Market by Molecule Type
4.1 Global Small Molecules Market by Region
4.2 Global Biologics Market by Region

Chapter 5. Global Ulcerative Colitis Market by Disease Type
5.1 Global Mild Market by Region
5.2 Global Moderate Market by Region
5.3 Global Severe Market by Region

Chapter 6. Global Ulcerative Colitis Market by Route of Administration
6.1 Global Oral Market by Region
6.2 Global Injectables Market by Region

Chapter 7. Global Ulcerative Colitis Market by Region
7.1 North America Ulcerative Colitis Market
7.1.1 North America Ulcerative Colitis Market by Molecule Type
7.1.1.1 North America Small Molecules Market by Country
7.1.1.2 North America Biologics Market by Country
7.1.2 North America Ulcerative Colitis Market by Disease Type
7.1.2.1 North America Mild Market by Country
7.1.2.2 North America Moderate Market by Country
7.1.2.3 North America Severe Market by Country
7.1.3 North America Ulcerative Colitis Market by Route of Administration
7.1.3.1 North America Oral Market by Country
7.1.3.2 North America Injectables Market by Country
7.1.4 North America Ulcerative Colitis Market by Country
7.1.4.1 US Ulcerative Colitis Market
7.1.4.1.1 US Ulcerative Colitis Market by Molecule Type
7.1.4.1.2 US Ulcerative Colitis Market by Disease Type
7.1.4.1.3 US Ulcerative Colitis Market by Route of Administration
7.1.4.2 Canada Ulcerative Colitis Market
7.1.4.2.1 Canada Ulcerative Colitis Market by Molecule Type
7.1.4.2.2 Canada Ulcerative Colitis Market by Disease Type
7.1.4.2.3 Canada Ulcerative Colitis Market by Route of Administration
7.1.4.3 Mexico Ulcerative Colitis Market
7.1.4.3.1 Mexico Ulcerative Colitis Market by Molecule Type
7.1.4.3.2 Mexico Ulcerative Colitis Market by Disease Type
7.1.4.3.3 Mexico Ulcerative Colitis Market by Route of Administration
7.1.4.4 Rest of North America Ulcerative Colitis Market
7.1.4.4.1 Rest of North America Ulcerative Colitis Market by Molecule Type
7.1.4.4.2 Rest of North America Ulcerative Colitis Market by Disease Type
7.1.4.4.3 Rest of North America Ulcerative Colitis Market by Route of Administration
7.2 Europe Ulcerative Colitis Market
7.2.1 Europe Ulcerative Colitis Market by Molecule Type
7.2.1.1 Europe Small Molecules Market by Country
7.2.1.2 Europe Biologics Market by Country
7.2.2 Europe Ulcerative Colitis Market by Disease Type
7.2.2.1 Europe Mild Market by Country
7.2.2.2 Europe Moderate Market by Country
7.2.2.3 Europe Severe Market by Country
7.2.3 Europe Ulcerative Colitis Market by Route of Administration
7.2.3.1 Europe Oral Market by Country
7.2.3.2 Europe Injectables Market by Country
7.2.4 Europe Ulcerative Colitis Market by Country
7.2.4.1 Germany Ulcerative Colitis Market
7.2.4.1.1 Germany Ulcerative Colitis Market by Molecule Type
7.2.4.1.2 Germany Ulcerative Colitis Market by Disease Type
7.2.4.1.3 Germany Ulcerative Colitis Market by Route of Administration
7.2.4.2 UK Ulcerative Colitis Market
7.2.4.2.1 UK Ulcerative Colitis Market by Molecule Type
7.2.4.2.2 UK Ulcerative Colitis Market by Disease Type
7.2.4.2.3 UK Ulcerative Colitis Market by Route of Administration
7.2.4.3 France Ulcerative Colitis Market
7.2.4.3.1 France Ulcerative Colitis Market by Molecule Type
7.2.4.3.2 France Ulcerative Colitis Market by Disease Type
7.2.4.3.3 France Ulcerative Colitis Market by Route of Administration
7.2.4.4 Russia Ulcerative Colitis Market
7.2.4.4.1 Russia Ulcerative Colitis Market by Molecule Type
7.2.4.4.2 Russia Ulcerative Colitis Market by Disease Type
7.2.4.4.3 Russia Ulcerative Colitis Market by Route of Administration
7.2.4.5 Spain Ulcerative Colitis Market
7.2.4.5.1 Spain Ulcerative Colitis Market by Molecule Type
7.2.4.5.2 Spain Ulcerative Colitis Market by Disease Type
7.2.4.5.3 Spain Ulcerative Colitis Market by Route of Administration
7.2.4.6 Italy Ulcerative Colitis Market
7.2.4.6.1 Italy Ulcerative Colitis Market by Molecule Type
7.2.4.6.2 Italy Ulcerative Colitis Market by Disease Type
7.2.4.6.3 Italy Ulcerative Colitis Market by Route of Administration
7.2.4.7 Rest of Europe Ulcerative Colitis Market
7.2.4.7.1 Rest of Europe Ulcerative Colitis Market by Molecule Type
7.2.4.7.2 Rest of Europe Ulcerative Colitis Market by Disease Type
7.2.4.7.3 Rest of Europe Ulcerative Colitis Market by Route of Administration
7.3 Asia Pacific Ulcerative Colitis Market
7.3.1 Asia Pacific Ulcerative Colitis Market by Molecule Type
7.3.1.1 Asia Pacific Small Molecules Market by Country
7.3.1.2 Asia Pacific Biologics Market by Country
7.3.2 Asia Pacific Ulcerative Colitis Market by Disease Type
7.3.2.1 Asia Pacific Mild Market by Country
7.3.2.2 Asia Pacific Moderate Market by Country
7.3.2.3 Asia Pacific Severe Market by Country
7.3.3 Asia Pacific Ulcerative Colitis Market by Route of Administration
7.3.3.1 Asia Pacific Oral Market by Country
7.3.3.2 Asia Pacific Injectables Market by Country
7.3.4 Asia Pacific Ulcerative Colitis Market by Country
7.3.4.1 China Ulcerative Colitis Market
7.3.4.1.1 China Ulcerative Colitis Market by Molecule Type
7.3.4.1.2 China Ulcerative Colitis Market by Disease Type
7.3.4.1.3 China Ulcerative Colitis Market by Route of Administration
7.3.4.2 Japan Ulcerative Colitis Market
7.3.4.2.1 Japan Ulcerative Colitis Market by Molecule Type
7.3.4.2.2 Japan Ulcerative Colitis Market by Disease Type
7.3.4.2.3 Japan Ulcerative Colitis Market by Route of Administration
7.3.4.3 India Ulcerative Colitis Market
7.3.4.3.1 India Ulcerative Colitis Market by Molecule Type
7.3.4.3.2 India Ulcerative Colitis Market by Disease Type
7.3.4.3.3 India Ulcerative Colitis Market by Route of Administration
7.3.4.4 South Korea Ulcerative Colitis Market
7.3.4.4.1 South Korea Ulcerative Colitis Market by Molecule Type
7.3.4.4.2 South Korea Ulcerative Colitis Market by Disease Type
7.3.4.4.3 South Korea Ulcerative Colitis Market by Route of Administration
7.3.4.5 Singapore Ulcerative Colitis Market
7.3.4.5.1 Singapore Ulcerative Colitis Market by Molecule Type
7.3.4.5.2 Singapore Ulcerative Colitis Market by Disease Type
7.3.4.5.3 Singapore Ulcerative Colitis Market by Route of Administration
7.3.4.6 Malaysia Ulcerative Colitis Market
7.3.4.6.1 Malaysia Ulcerative Colitis Market by Molecule Type
7.3.4.6.2 Malaysia Ulcerative Colitis Market by Disease Type
7.3.4.6.3 Malaysia Ulcerative Colitis Market by Route of Administration
7.3.4.7 Rest of Asia Pacific Ulcerative Colitis Market
7.3.4.7.1 Rest of Asia Pacific Ulcerative Colitis Market by Molecule Type
7.3.4.7.2 Rest of Asia Pacific Ulcerative Colitis Market by Disease Type
7.3.4.7.3 Rest of Asia Pacific Ulcerative Colitis Market by Route of Administration
7.4 LAMEA Ulcerative Colitis Market
7.4.1 LAMEA Ulcerative Colitis Market by Molecule Type
7.4.1.1 LAMEA Small Molecules Market by Country
7.4.1.2 LAMEA Biologics Market by Country
7.4.2 LAMEA Ulcerative Colitis Market by Disease Type
7.4.2.1 LAMEA Mild Market by Country
7.4.2.2 LAMEA Moderate Market by Country
7.4.2.3 LAMEA Severe Market by Country
7.4.3 LAMEA Ulcerative Colitis Market by Route of Administration
7.4.3.1 LAMEA Oral Market by Country
7.4.3.2 LAMEA Injectables Market by Country
7.4.4 LAMEA Ulcerative Colitis Market by Country
7.4.4.1 Brazil Ulcerative Colitis Market
7.4.4.1.1 Brazil Ulcerative Colitis Market by Molecule Type
7.4.4.1.2 Brazil Ulcerative Colitis Market by Disease Type
7.4.4.1.3 Brazil Ulcerative Colitis Market by Route of Administration
7.4.4.2 Argentina Ulcerative Colitis Market
7.4.4.2.1 Argentina Ulcerative Colitis Market by Molecule Type
7.4.4.2.2 Argentina Ulcerative Colitis Market by Disease Type
7.4.4.2.3 Argentina Ulcerative Colitis Market by Route of Administration
7.4.4.3 UAE Ulcerative Colitis Market
7.4.4.3.1 UAE Ulcerative Colitis Market by Molecule Type
7.4.4.3.2 UAE Ulcerative Colitis Market by Disease Type
7.4.4.3.3 UAE Ulcerative Colitis Market by Route of Administration
7.4.4.4 Saudi Arabia Ulcerative Colitis Market
7.4.4.4.1 Saudi Arabia Ulcerative Colitis Market by Molecule Type
7.4.4.4.2 Saudi Arabia Ulcerative Colitis Market by Disease Type
7.4.4.4.3 Saudi Arabia Ulcerative Colitis Market by Route of Administration
7.4.4.5 South Africa Ulcerative Colitis Market
7.4.4.5.1 South Africa Ulcerative Colitis Market by Molecule Type
7.4.4.5.2 South Africa Ulcerative Colitis Market by Disease Type
7.4.4.5.3 South Africa Ulcerative Colitis Market by Route of Administration
7.4.4.6 Nigeria Ulcerative Colitis Market
7.4.4.6.1 Nigeria Ulcerative Colitis Market by Molecule Type
7.4.4.6.2 Nigeria Ulcerative Colitis Market by Disease Type
7.4.4.6.3 Nigeria Ulcerative Colitis Market by Route of Administration
7.4.4.7 Rest of LAMEA Ulcerative Colitis Market
7.4.4.7.1 Rest of LAMEA Ulcerative Colitis Market by Molecule Type
7.4.4.7.2 Rest of LAMEA Ulcerative Colitis Market by Disease Type
7.4.4.7.3 Rest of LAMEA Ulcerative Colitis Market by Route of Administration

Chapter 8. Company Profiles
8.1 Abbott Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.2 Ajinomoto Co., Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental & Regional Analysis
8.2.4 Research & Development Expenses
8.3 AstraZeneca PLC
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expenses
8.4 GlaxoSmithKline PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.5 Johnson & Johnson
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental &Regional Analysis
8.5.4 Research & Development Expenses
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.7 Pfizer, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional & Segmental Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Approvals and Trials:
8.8 Sanofi S.A.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.9 InDex Pharmaceuticals Holding AB
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Recent strategies and developments:
8.9.3.1 Partnerships, Collaborations, and Agreements:
8.10. Eli Lilly And Company
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expenses

TABLE 1 Global Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 2 Global Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 3 Global Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 4 Global Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 5 Global Small Molecules Market by Region, 2018 - 2021, USD Million
TABLE 6 Global Small Molecules Market by Region, 2022 - 2028, USD Million
TABLE 7 Global Biologics Market by Region, 2018 - 2021, USD Million
TABLE 8 Global Biologics Market by Region, 2022 - 2028, USD Million
TABLE 9 Global Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 10 Global Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 11 Global Mild Market by Region, 2018 - 2021, USD Million
TABLE 12 Global Mild Market by Region, 2022 - 2028, USD Million
TABLE 13 Global Moderate Market by Region, 2018 - 2021, USD Million
TABLE 14 Global Moderate Market by Region, 2022 - 2028, USD Million
TABLE 15 Global Severe Market by Region, 2018 - 2021, USD Million
TABLE 16 Global Severe Market by Region, 2022 - 2028, USD Million
TABLE 17 Global Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 18 Global Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 19 Global Oral Market by Region, 2018 - 2021, USD Million
TABLE 20 Global Oral Market by Region, 2022 - 2028, USD Million
TABLE 21 Global Injectables Market by Region, 2018 - 2021, USD Million
TABLE 22 Global Injectables Market by Region, 2022 - 2028, USD Million
TABLE 23 Global Ulcerative Colitis Market by Region, 2018 - 2021, USD Million
TABLE 24 Global Ulcerative Colitis Market by Region, 2022 - 2028, USD Million
TABLE 25 North America Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 26 North America Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 27 North America Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 28 North America Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 29 North America Small Molecules Market by Country, 2018 - 2021, USD Million
TABLE 30 North America Small Molecules Market by Country, 2022 - 2028, USD Million
TABLE 31 North America Biologics Market by Country, 2018 - 2021, USD Million
TABLE 32 North America Biologics Market by Country, 2022 - 2028, USD Million
TABLE 33 North America Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 34 North America Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 35 North America Mild Market by Country, 2018 - 2021, USD Million
TABLE 36 North America Mild Market by Country, 2022 - 2028, USD Million
TABLE 37 North America Moderate Market by Country, 2018 - 2021, USD Million
TABLE 38 North America Moderate Market by Country, 2022 - 2028, USD Million
TABLE 39 North America Severe Market by Country, 2018 - 2021, USD Million
TABLE 40 North America Severe Market by Country, 2022 - 2028, USD Million
TABLE 41 North America Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 North America Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 North America Oral Market by Country, 2018 - 2021, USD Million
TABLE 44 North America Oral Market by Country, 2022 - 2028, USD Million
TABLE 45 North America Injectables Market by Country, 2018 - 2021, USD Million
TABLE 46 North America Injectables Market by Country, 2022 - 2028, USD Million
TABLE 47 North America Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
TABLE 48 North America Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
TABLE 49 US Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 50 US Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 51 US Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 52 US Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 53 US Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 54 US Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 55 US Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 56 US Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 57 Canada Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 58 Canada Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 59 Canada Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 60 Canada Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 61 Canada Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 62 Canada Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 63 Canada Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 64 Canada Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 65 Mexico Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 66 Mexico Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 67 Mexico Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 68 Mexico Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 69 Mexico Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 70 Mexico Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 71 Mexico Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 72 Mexico Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 73 Rest of North America Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 74 Rest of North America Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 75 Rest of North America Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 76 Rest of North America Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 77 Rest of North America Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 78 Rest of North America Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 79 Rest of North America Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 80 Rest of North America Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 81 Europe Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 82 Europe Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 83 Europe Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 84 Europe Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 85 Europe Small Molecules Market by Country, 2018 - 2021, USD Million
TABLE 86 Europe Small Molecules Market by Country, 2022 - 2028, USD Million
TABLE 87 Europe Biologics Market by Country, 2018 - 2021, USD Million
TABLE 88 Europe Biologics Market by Country, 2022 - 2028, USD Million
TABLE 89 Europe Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 90 Europe Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 91 Europe Mild Market by Country, 2018 - 2021, USD Million
TABLE 92 Europe Mild Market by Country, 2022 - 2028, USD Million
TABLE 93 Europe Moderate Market by Country, 2018 - 2021, USD Million
TABLE 94 Europe Moderate Market by Country, 2022 - 2028, USD Million
TABLE 95 Europe Severe Market by Country, 2018 - 2021, USD Million
TABLE 96 Europe Severe Market by Country, 2022 - 2028, USD Million
TABLE 97 Europe Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 98 Europe Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 99 Europe Oral Market by Country, 2018 - 2021, USD Million
TABLE 100 Europe Oral Market by Country, 2022 - 2028, USD Million
TABLE 101 Europe Injectables Market by Country, 2018 - 2021, USD Million
TABLE 102 Europe Injectables Market by Country, 2022 - 2028, USD Million
TABLE 103 Europe Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
TABLE 104 Europe Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
TABLE 105 Germany Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 106 Germany Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 107 Germany Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 108 Germany Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 109 Germany Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 110 Germany Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 111 Germany Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 112 Germany Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 113 UK Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 114 UK Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 115 UK Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 116 UK Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 117 UK Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 118 UK Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 119 UK Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 120 UK Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 121 France Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 122 France Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 123 France Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 124 France Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 125 France Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 126 France Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 127 France Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 128 France Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 129 Russia Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 130 Russia Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 131 Russia Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 132 Russia Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 133 Russia Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 134 Russia Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 135 Russia Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 136 Russia Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 137 Spain Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 138 Spain Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 139 Spain Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 140 Spain Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 141 Spain Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 142 Spain Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 143 Spain Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 144 Spain Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 145 Italy Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 146 Italy Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 147 Italy Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 148 Italy Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 149 Italy Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 150 Italy Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 151 Italy Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 152 Italy Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 153 Rest of Europe Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 154 Rest of Europe Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 155 Rest of Europe Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 156 Rest of Europe Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 157 Rest of Europe Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 158 Rest of Europe Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 159 Rest of Europe Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 160 Rest of Europe Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 161 Asia Pacific Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 162 Asia Pacific Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 163 Asia Pacific Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 164 Asia Pacific Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 165 Asia Pacific Small Molecules Market by Country, 2018 - 2021, USD Million
TABLE 166 Asia Pacific Small Molecules Market by Country, 2022 - 2028, USD Million
TABLE 167 Asia Pacific Biologics Market by Country, 2018 - 2021, USD Million
TABLE 168 Asia Pacific Biologics Market by Country, 2022 - 2028, USD Million
TABLE 169 Asia Pacific Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 170 Asia Pacific Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 171 Asia Pacific Mild Market by Country, 2018 - 2021, USD Million
TABLE 172 Asia Pacific Mild Market by Country, 2022 - 2028, USD Million
TABLE 173 Asia Pacific Moderate Market by Country, 2018 - 2021, USD Million
TABLE 174 Asia Pacific Moderate Market by Country, 2022 - 2028, USD Million
TABLE 175 Asia Pacific Severe Market by Country, 2018 - 2021, USD Million
TABLE 176 Asia Pacific Severe Market by Country, 2022 - 2028, USD Million
TABLE 177 Asia Pacific Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 178 Asia Pacific Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 179 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
TABLE 180 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
TABLE 181 Asia Pacific Injectables Market by Country, 2018 - 2021, USD Million
TABLE 182 Asia Pacific Injectables Market by Country, 2022 - 2028, USD Million
TABLE 183 Asia Pacific Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
TABLE 184 Asia Pacific Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
TABLE 185 China Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 186 China Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 187 China Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 188 China Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 189 China Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 190 China Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 191 China Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 192 China Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 193 Japan Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 194 Japan Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 195 Japan Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 196 Japan Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 197 Japan Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 198 Japan Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 199 Japan Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 200 Japan Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 201 India Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 202 India Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 203 India Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 204 India Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 205 India Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 206 India Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 207 India Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 208 India Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 209 South Korea Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 210 South Korea Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 211 South Korea Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 212 South Korea Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 213 South Korea Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 214 South Korea Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 215 South Korea Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 216 South Korea Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 217 Singapore Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 218 Singapore Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 219 Singapore Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 220 Singapore Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 221 Singapore Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 222 Singapore Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 223 Singapore Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 224 Singapore Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 225 Malaysia Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 226 Malaysia Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 227 Malaysia Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 228 Malaysia Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 229 Malaysia Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 230 Malaysia Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 231 Malaysia Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 232 Malaysia Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 233 Rest of Asia Pacific Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 234 Rest of Asia Pacific Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 235 Rest of Asia Pacific Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 236 Rest of Asia Pacific Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 237 Rest of Asia Pacific Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 238 Rest of Asia Pacific Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 239 Rest of Asia Pacific Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 240 Rest of Asia Pacific Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 241 LAMEA Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 242 LAMEA Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 243 LAMEA Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 244 LAMEA Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 245 LAMEA Small Molecules Market by Country, 2018 - 2021, USD Million
TABLE 246 LAMEA Small Molecules Market by Country, 2022 - 2028, USD Million
TABLE 247 LAMEA Biologics Market by Country, 2018 - 2021, USD Million
TABLE 248 LAMEA Biologics Market by Country, 2022 - 2028, USD Million
TABLE 249 LAMEA Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 250 LAMEA Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 251 LAMEA Mild Market by Country, 2018 - 2021, USD Million
TABLE 252 LAMEA Mild Market by Country, 2022 - 2028, USD Million
TABLE 253 LAMEA Moderate Market by Country, 2018 - 2021, USD Million
TABLE 254 LAMEA Moderate Market by Country, 2022 - 2028, USD Million
TABLE 255 LAMEA Severe Market by Country, 2018 - 2021, USD Million
TABLE 256 LAMEA Severe Market by Country, 2022 - 2028, USD Million
TABLE 257 LAMEA Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 258 LAMEA Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 259 LAMEA Oral Market by Country, 2018 - 2021, USD Million
TABLE 260 LAMEA Oral Market by Country, 2022 - 2028, USD Million
TABLE 261 LAMEA Injectables Market by Country, 2018 - 2021, USD Million
TABLE 262 LAMEA Injectables Market by Country, 2022 - 2028, USD Million
TABLE 263 LAMEA Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
TABLE 264 LAMEA Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
TABLE 265 Brazil Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 266 Brazil Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 267 Brazil Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 268 Brazil Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 269 Brazil Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 270 Brazil Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 271 Brazil Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 272 Brazil Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 273 Argentina Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 274 Argentina Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 275 Argentina Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 276 Argentina Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 277 Argentina Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 278 Argentina Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 279 Argentina Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 280 Argentina Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 281 UAE Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 282 UAE Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 283 UAE Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 284 UAE Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 285 UAE Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 286 UAE Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 287 UAE Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 288 UAE Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 289 Saudi Arabia Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 290 Saudi Arabia Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 291 Saudi Arabia Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 292 Saudi Arabia Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 293 Saudi Arabia Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 294 Saudi Arabia Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 295 Saudi Arabia Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 296 Saudi Arabia Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 297 South Africa Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 298 South Africa Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 299 South Africa Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 300 South Africa Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 301 South Africa Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 302 South Africa Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 303 South Africa Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 304 South Africa Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 305 Nigeria Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 306 Nigeria Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 307 Nigeria Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 308 Nigeria Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 309 Nigeria Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 310 Nigeria Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 311 Nigeria Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 312 Nigeria Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 313 Rest of LAMEA Ulcerative Colitis Market, 2018 - 2021, USD Million
TABLE 314 Rest of LAMEA Ulcerative Colitis Market, 2022 - 2028, USD Million
TABLE 315 Rest of LAMEA Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
TABLE 316 Rest of LAMEA Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
TABLE 317 Rest of LAMEA Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
TABLE 318 Rest of LAMEA Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
TABLE 319 Rest of LAMEA Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
TABLE 320 Rest of LAMEA Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
TABLE 321 Key Information – Abbott Laboratories
TABLE 322 Key information – Ajinomoto Co., Inc.
TABLE 323 KEY INFORMATION – ASTRAZENECA PLC
TABLE 324 Key Information – GlaxoSmithKline PLC
TABLE 325 Key information – Johnson & Johnson
TABLE 326 KEY INFORMATION - MERCK & CO., INC.
TABLE 327 Key Information – Pfizer, Inc.
TABLE 328 Key Information – Sanofi S.A.
TABLE 329 Key Information – InDex Pharmaceuticals Holding AB
TABLE 330 Key Information – Eli Lilly And Company

List of Figures
FIG 1 Methodology for the research
FIG 2 Global Ulcerative Colitis Market Share by Molecule Type, 2021
FIG 3 Global Ulcerative Colitis Market Share by Molecule Type, 2028
FIG 4 Global Ulcerative Colitis Market by Molecule Type, 2018 - 2028, USD Million
FIG 5 Global Ulcerative Colitis Market Share by Disease Type, 2021
FIG 6 Global Ulcerative Colitis Market Share by Disease Type, 2028
FIG 7 Global Ulcerative Colitis Market by Disease Type, 2018 - 2028, USD Million
FIG 8 Global Ulcerative Colitis Market Share by Route of Administration, 2021
FIG 9 Global Ulcerative Colitis Market Share by Route of Administration, 2028
FIG 10 Global Ulcerative Colitis Market by Route of Administration, 2018 - 2028, USD Million
FIG 11 Global Ulcerative Colitis Market Share by Region, 2021
FIG 12 Global Ulcerative Colitis Market Share by Region, 2028
FIG 13 Global Ulcerative Colitis Market by Region, 2018 - 2028, USD Million